Table 1

Individual tumor characteristics, mutation, and CGH analyses
Tumor1
 mtr2
 Stage/grade3
 FGFR3mut4,5
 TP53mut4
 Imbalances6
01.I
TaG2

dim (8p., 22p, 22q11–13.1)





enh (8q11–q22, Xq)
01.R1
 5
 TaG2

dim (8p)





enh (8q)
02.I
T2G3

dim (19p)





enh (1p31–p32, 1q23–q25, 8q, 12q13–q21)
02.R1
 7
 T2G3

enh (1q23–q24, 2p14-pter, 3p22-pter)
07.I
TaG1
 S249C
na
07.R1
 7
 TaG2
 S249C
 K132N
 na
09.I
T1G3
G245D
 dim (2q33-qter, 6q24-qter, 9, 10q, 11p15-pter, 17, 22)





enh (1p11–p21, 1q11–q31, 2q11, 2q23–q24, 3, 8q11–q22, 11q14-qter, 16p, 16q11–q13, 18p, 20, X)
09.R1
 10
 TIG3
G245D
 dim (9)





enh (1q22–q31, 2p13-pter, 3, 8, 16p, 16q11–q13, 20)
10.I
T1G2
 S249C
 R280T
 dim (9q)





enh (12q13–q21)
10.R1
 5
 T1G3
 S249C
 R280T
 dim (9q22-qter, 10q24-qter)





enh (10q21–q23, 20q, Xp, Xq11–q24)
13.I
T1G2

dim (9q, 10p12–p13, 16p, 17p, 19, 22)





enh (1p11–p31, 1q11–q41, 3, 5q14–q23, 8q13-qter, 12q15–q22, 13, 18q, 20p, X)
13.R1
 6
 T0

dim (4, 9, 17p, 19)





enh (1q23-qter, 3, 5q13–q23, 13, 14, 17q, 18q, 20, X)
14.I
T1G2

dim (8p, 9, 10p, 17p)





enh (8q)
14.R1
 8
 T1G3

dim (9, 10p, 19)





enh (8q)
16.I
TIG3

dim (8q)





enh (8p, 19)
16.R1
 4
 T1G2

dim (8q)
18.I
T1G2

dim (8p)





enh (1p32-pter, 1p13–p21, 1q21–q31, 1q33–q35, 3, 5p, 6p11–p22, 8q21-qter, 10q11–q23, 13q22-qter)
18.R1
 16
 T2G3
R273L
 enh (3, 8q11–q23, 9p)
21.I
TaG2

dim (9q22-qter, 11p13-qter, 22)





enh (12p11–p12, 12q11–q23)
21.R1
 7
 T1G2

dim (8p, 9q, 10p, 11p, 11q11–q13.1, 12q24-qter, 16p, 17, 18p, 19, 22)





enh (3, 4p11–p15, 4q11–q32, 5q21–q23, 6q11–q14, 8q, 12q15–q21, 13q14-qter, 18q11–q22)
29.I
TaG2
 S249C
dim (9q32-qter, 14q23-qter, 19)





enh (1q22-qter, 8q)
29.R1
 21
 TaG2
 S249C
dim (9q22-qter)





enh (1q11–q31, 13, X)
30.I
TaG2

na
30.R1
 13
 TaG2

na
31.I
TaG2
R290H
 na
31.R1
 10
 TaG2

na
31.R2
 17
 TaG2

dim (2q34-qter, 8p, 14, 19p)





enh (1q21-qter, 2p13-pter, 5p13-pter, 8q, 11q14–q24)
31.R3
 19
 T4G3

dim (2q31–q34, 5q11–q23, 6q, 9p12-pter)





enh (1q23–q24, 1q32-qter, 2p, 2q11–q14, 5p, 8)
34.I
T1G3
 S249C
dim (9, 11p11-pter, 12p)





enh (1p31–p32, 1q23–q41)
34.R1
 6
 T2G3
 S249C
dim (8p, 9)





enh (8q)
38.I
T1G3
R248Q
 dim (9)
38.R1
 9
 T2G3
R248Q
 na
38.R2
 24
 T2G3
R248Q
 dim (19p)





enh (2q14–q21, 8q22-qter)
42.I
TaG2
 S249C
dim (5q, 10q11–q21, 10q23-qter, 13p, 13q11–q14, 15, 17p, 18q, 19p)





enh (2p13-pter, 3, 5p, 6p22-pter, 8q13-qter, 9p22.1-pter, 12q14–q21.2, 18p, X)
42.R1
 31
 TaG1
 S249C
enh (1q24-qter, 8q21–q23)
43.I
TaG1
 S249C
na
43.R1
 4
 TaG1
 Y375C
na
47.I
TaG2

na
47.R1
 5
 TaG2

na
47.R2
 18
 TaG1

na
53.I
TaG2
 S249C
enh (X)
53.R1.S1
 27
 T1G2
 S249C
dim (19p)
53.R1.S2
 27
 T1G2
 S249C
dim (19p)





enh (Xp11-pter, Xq26-qter)
54.S1
 -
 T1G3

enh (1q23)
54.S2
 -
 T1G3

enh (8q21-qter, 12, 13)
56.S1
 -
 T2G3

dim (2q32.2-qter, 5q, 15, 16q)





enh (1p, 1q12–q23, 3, 5p, 8q, 13q21-qter, 16p, 17q, 20, 21, Xp22-pter)
56.S2
 -
 T2G3
Q331STOP
 dim (8p)





enh (1, 2p, 2q11–q21, 3, 5p, 6p12-pter, 6q21–q23, 7p, 7q32-qter, 8q, 10p, 15q21-qter, 20)
64.S1
 -
 T3G3
 na
 na
 na
64.S2
 -
 T3G3
 na
 na
 na

1I, Initial tumor, i.e. the first resected tumor from a given patient; R, recurrent tumor; S, synchronous tumor.

2mtr, months to recurrence

3Histopathological staging and grading were reviewed according to the 2002 TNM and 1999 WHO classification systems by one single pathologist (GC)

4 Direct sequencing of exons 7, 10, and 15 of FGFR3 and exons 4 to 9 of TP53 was performed using BigDye terminator chemistry (Applied Biosystems, Foster City, CA). na, data not available either due no PCR products for sequencing or DNA quality unsuitable for CGH.

5FGFR3 amino acid positions are given according to the FGFR3 IIIb open reading frame; n/a, sequence data not available.

6Partial chromosomal losses in initial tumors incompatible with imbalances present in recurring tumors are in bold

Lindgren et al. BMC Cancer 2008 8:183   doi:10.1186/1471-2407-8-183